Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1.
- Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor - Astellas Pharma Inc. (TSE:4503, President
- If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L1 inhibitor Astellas Pharma Inc. (TSE:4503, President and CEO:
Astellas took a look five years ahead Wednesday, and the view is good, with increased sales estimates for key drugs such as Pfizer-partnered Xtandi and Seagen-shared Padcev. The plan for $16.5 billion sales by fiscal 2025 is definitely upbeat, but it still “looks realistic” in one analyst's eyes.
SINGAPORE: Malaysia and Singapore have agreed on the procedures and entry requirements for compassionate and emergency visits between their peoples amid stricter border measures.
The Death and Critically Ill Emergency Visits (DCEV) arrangement will be implemented from May 17, according to a joint statement issued yesterday by Foreign Minister Datuk Seri Hishammuddin Hussein and his Singapore counterpart Dr Vivian Balakrishnan.
“This agreement provides a framework to facilitate travel between the two countries for compassionate and emergency reasons, ” it said.
Details of the procedures and entry requirements will be released by the Malaysian Immigration Department and the Immigration and Checkpoints Authority of Singapore.